Want to see ACOG full AI Analyst Report?
ACOG Stock Chart & Stats
$7.90
$0.68(8.61%)
At close: 4:00 PM EDT
$7.90
$0.68(8.61%)
Day’s Range― - ―
52-Week Range$4.50 - $10.00
Previous Close$8.58
Volume108.17K
Average Volume (3M)87.53K
Market Cap
$186.75M
Enterprise Value$115.77
Total Cash (Recent Filing)$41.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Dec 01, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding21,777,868
10 Day Avg. Volume111,240
30 Day Avg. Volume87,535
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.84
Price to Sales (P/S)11.24
P/FCF Ratio-5.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.00Price Target Upside127.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$25.41M
Bulls Say, Bears Say
Bulls Say
Commercial Adoption And Revenue GrowthRapid revenue growth alongside higher bottle volumes, a broader prescriber base, repeat prescriptions, and nursing-home adoption indicates genuine product uptake. Continued utilization within existing accounts could support a durable commercial expansion beyond initial launch demand.
Strong Product Gross EconomicsA very high product margin provides substantial gross-profit potential as sales scale, while eliminating the future royalty burden improves long-term product economics. These factors can help fund commercial investment and accelerate the path toward operating profitability.
Debt-Free Balance SheetThe absence of reported debt reduces solvency and interest-burden risk during commercialization. Meaningful cash, current assets, and working capital provide operating flexibility to support launch activities and clinical programs while management works toward profitability.
Bears Say
Persistent Losses And Cash BurnThe company remains dependent on external funding because operating activities consume substantial cash and losses remain large relative to revenue. If commercialization does not scale quickly enough, additional financing could pressure the equity base and dilute shareholders.
Payer Access And Gross-to-Net PressureLimited formulary coverage restricts patient access and can delay prescription conversion even when prescriber demand is improving. Elevated gross-to-net deductions also reduce realized revenue, making the commercial ramp more dependent on future payer wins.
Reliance On Future Clinical EvidenceMeaningful payer persuasion and promotional support depend partly on upcoming evidence rather than already established datasets. Delays, weaker-than-expected results, or slow publication could postpone coverage gains and extend the period of operating losses.
Alpha Cognition Inc News
ACOG FAQ
What was Alpha Cognition Inc’s price range in the past 12 months?
Alpha Cognition Inc lowest stock price was $4.50 and its highest was $10.00 in the past 12 months.
What is Alpha Cognition Inc’s market cap?
Alpha Cognition Inc’s market cap is $186.75M.
When is Alpha Cognition Inc’s upcoming earnings report date?
Alpha Cognition Inc’s upcoming earnings report date is Dec 01, 2026 which is in 103 days.
How were Alpha Cognition Inc’s earnings last quarter?
Alpha Cognition Inc released its earnings results on Aug 13, 2026. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.392 by -$0.008.
Is Alpha Cognition Inc overvalued?
According to Wall Street analysts Alpha Cognition Inc’s price is currently Undervalued.
Does Alpha Cognition Inc pay dividends?
Alpha Cognition Inc does not currently pay dividends.
What is Alpha Cognition Inc’s EPS estimate?
Alpha Cognition Inc’s EPS estimate is -0.34.
How many shares outstanding does Alpha Cognition Inc have?
Alpha Cognition Inc has 21,777,868 shares outstanding.
What happened to Alpha Cognition Inc’s price movement after its last earnings report?
Alpha Cognition Inc reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.392. Following the earnings report the stock price went up 2.433%.
Which hedge fund is a major shareholder of Alpha Cognition Inc?
Currently, no hedge funds are holding shares in ACOG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Cognition Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (127.85% Upside)
$18.00 (127.85% Upside)
Blogger Sentiment
Bullish
ACOG Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 16.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
42.99%
Trailing 12-Months
Company Description
Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
ACOG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum for ZUNVEYL: rapid sequential revenue growth (71% QoQ), healthy gross margins (~94%), improving net loss, robust organic demand (37% bottle growth) and encouraging prescriber/facility repeat metrics. Management is deliberately investing to scale commercial capabilities and evidence generation (BEACON positive; CONVERGE topline expected Q3). Key challenges are slower-than-expected payer/formulary activation, limited contracted coverage (~16%), and dependence on upcoming data and policy-driven plan behavior; the company remains unprofitable but projects operating profitability in 2027. On balance, the positive commercial execution and financial improvements outweigh the access and timing headwinds, with upside from future payer conversions.View all ACOG earnings summariesACOG Stock 12 Month Forecast
Average Price Target
$18.00
▲(127.85% Upside)
Technical Analysis
Ownership Overview
20.16% Insiders
0.06% Mutual Funds
46.34% Other Institutional Investors
33.44% Public Companies and
Individual Investors